JAMA: Medical treatment of new coronary pneumonia

JAMA: Medical treatment of new coronary pneumonia
April 17, 2020 No Comments News customjune.com

The 2019 coronavirus disease (COVID-19) pandemic caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently lacking effective preventive and therapeutic drugs. In view of the spread of the epidemic, clinicians need accurate evidence that a certain drug under investigation is effective against new coronavirus infection.Although there is currently no effective treatment for the new coronavirus, as the understanding of the virus deepens, scientists have proposed a large number of potential drug targets. At present, the most promising therapy is redcive. Redoxir has strong in vitro activity against SARS-CoV-2, but it has not yet obtained approval from the US Food and Drug Administration, and a corresponding randomized clinical trial is in progress. It has been confirmed that oseltamivir cannot treat new coronary pneumonia. Corticosteroids are currently not recommended. Current clinical evidence does not support discontinuation of angiotensin converting enzyme inhibitors or angiotensin receptor blockers in COVID-19 patients.The COVID-19 pandemic is the most severe global public health crisis in recent years, and it may be the most serious crisis since the outbreak of the pandemic influenza in 1918. In order to find potential treatments for COVID-19, scientists quickly started a large number of clinical trials, but so far no effective drug treatments have been shown.

About The Author

Leave a reply

Your email address will not be published. Required fields are marked *